Tecartus
Gilead Sciences to Lay Off 72 Employees, Shutter Seattle Office
The cuts, which will go into effect mid-January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.
Gilead has high hopes that anito-cel, a multiple myeloma cell therapy it is developing with Arcellx, can bolster its cell therapy franchise.
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Revenues for the firm's antibody-drug conjugate Trodelvy grew 39 percent year over year in Q1 2024 due to increased demand.
FDA Requires Boxed Warning of Secondary Cancer Risk for Autologous CAR T-Cell Therapies
The requirement comes after FDA investigated data showing patients developed secondary T-cell malignancies after CD19- and BCMA-directed CAR T-cell therapies.